Insmed Inc (INSM : NASDAQ)
Common Stock
$100.48
USD
-1.26 (-1.24%)
Last updated: 2026-10-08
Follow INSM
INSM
Insmed Inc
WealthAwesomePerformance
1 Day
-1.24%
1 Week
-7.47%
1 Month
-19.55%
YTD
-43.27%
Key Statistics
Market Cap
$21.94B
52W High
$212.75
52W Low
$90.39
P/E Ratio
-
50 Day MA
$119.72
200 Day MA
$131.81
Beta
0.82
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/8/2026 | $100.66 | $101.06 | $96.68 | $100.48 | $100.48 | 5,084,419 |
| 10/7/2026 | $103.87 | $104.80 | $101.60 | $101.74 | $101.74 | 3,161,376 |
| 10/6/2026 | $103.97 | $107.87 | $101.32 | $105.23 | $105.23 | 3,685,700 |
| 10/5/2026 | $105.50 | $108.75 | $101.65 | $103.83 | $103.83 | 5,393,837 |
| 10/2/2026 | $107.76 | $111.54 | $105.68 | $111.12 | $111.12 | 4,136,200 |
| 10/1/2026 | $114.68 | $116.19 | $108.48 | $108.59 | $108.59 | 2,646,300 |
| 9/30/2026 | $115.65 | $116.43 | $113.60 | $114.14 | $114.14 | 2,868,400 |
| 9/29/2026 | $117.06 | $118.50 | $114.49 | $115.63 | $115.63 | 1,668,200 |
| 9/28/2026 | $116.83 | $119.32 | $116.31 | $117.67 | $117.67 | 1,744,400 |
| 9/25/2026 | $121.87 | $122.90 | $115.87 | $117.83 | $117.83 | 2,672,700 |
Analyst Price Targets
Based on 24 analysts covering INSM · as of Oct 5, 2026
Wall Street analysts forecast INSM stock price to rise 96.8% over the next 12 months.
Consensus
Strong Buy4.79 / 5.00
Avg. Target
US$197.74
+96.8% Upside
Current Price
US$100.48
Last close
Analyst Breakdown (24 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on INSM's historical volatility
30-Day Vol
41.7%
Annualized
90-Day Vol
65.9%
Annualized
Trend (90d)
-37.3%
Annualized drift
90d Mean
US$87.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$96.12 | US$83.24 – US$110.98 |
| 60 trading days | US$91.94 | US$75.02 – US$112.68 |
| 90 trading days | US$87.95 | US$68.56 – US$112.83 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Financials
- Revenue (TTM)
- $1.14B
- EBITDA
- $-794.96M
- Profit Margin
- -76.94%
- ROE (TTM)
- -87.22%
- EPS (Diluted)
- -4.10
- Book Value
- 3.47
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About INSM.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| FLYE | Fly-E Group, Inc. Common Stock | $2.32 | +82.68% |
| JZ | Jianzhi Education Technology Group Company Limited American Depositary Shares | $0.83 | +77.52% |
| EURKR | Eureka Acquisition Corp Right | $0.44 | +62.87% |
| AIXI | XIAO-I Corporation | $1.93 | +46.21% |
| PCRX | Pacira BioSciences, Inc. | $36.39 | +44.40% |
| QNME | Quanome Technologies, Inc. | $0.83 | +43.28% |
| OLB | OLB Group Inc | $0.55 | +41.86% |
| RITRF | Reitar Logtech Holdings Limited | $0.01 | +33.33% |
INSM.US news timeline
1 article covering INSM.US, most recent first
Latest